SHORT-TERM (6 MONTHS) EFFECTS OF TAMOXIFEN ON THE CONTRALATERAL BREAST PARENCHYMA IN PATIENTS WHO HAVE UNDERGONE SURGERY FOR BREAST CANCER: SIGNIFICANCE OF MAMMOGRAPHY IN THE RADIOLOGIC EVALUATION OF BREAST PARENCHYMA

Year 2003, Volume: 16 Issue: 3, 188 - 194, 03.12.2016

Arda Kayhan İhsan Nuri Akpınar Ozan Belli Erkin Arıbal

Abstract

Objective: Our aim is to radiologically evaluate the effects of tamoxifen on the contralateral breast parenchyma in patients who have undergone surgery for breast cancer.
Materials and Methods: We examined the mammograms of 121 women; 88 of them had breast cancer and 33 were healthy controls. The patients were grouped as follows; I: patients who received tamoxifen therapy after surgery, II: patients who did not take tamoxifen and III: healthy controls. The breast parenchyma area, the visualization of Cooper’s ligaments and lactiferous ducts were evaluated in all 3 groups and analyzed statistically In order to determine the changes in breast density.
Results: In patients who had undergone tamoxifen therapy, compared to non-tamoxifen patients, there was a prominent reduction in breast parenchyma (p<0.0001). This effect was more significant in premenopausal women (p<0.005). The effect of tamoxifen was most evident at the first 6th month follow-up.
Conclusion: Tamoxifen reduces breast
parenchyma and mammography is an objective
method for demonstrating this reduction as a decrease in breast density.
Key Words: Tamoxifen, Breast carcinoma, Mammography, Breast parenchyma.

References

• Petri k DW, NcCready DR, Goel V, Pinfold SP, Sawka CA. The rate of breast- conserving surgery for early breast cancer is not influenced by the surgical strategy of excisional biipsy followed by the definitive procedure. The Breast J 2001; 7: 158-165.
• national Cancer Institute of Canada. Canadian Cancer Statistics 2000. Toronto: national Canser Institute of Canada, 2000.
• Dunn KB, Ford LG. From adjuvant therapy to breast cancer prevention: BCPT and STAR. The Breast J 2001; 7: 144-157.
• Brisson J, Brisson B, Cote G, Maunsell E, Berube S, Robert J. Tamoxifen and mammographic breast densities. Cancer
• Erkin Anbal, et al.
• Epidemiol Biomarkers Frev 2000; 9: 911- 915.
• Harper MJ, Walpole AL. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. nature 1966; 212: 85-92.
• Klopper A, Hall N. Hew synthetic agent for the induction of ovulation: Preliminary trial in women. Br Ned J 1971; 2: 152-154.
• Williamson JG, Ellis JD. The induction of ovulation by tamoxifen. J Obstet Gynaecol Br Commonw 1973; 80: 844- 847.
• Furr BJA, Jordan VC. The pharmacology and clinical tamoxifen. Pharmacol Ther 1984; 25: 127-205.
• Eeig. S.Æ Breast masses.Nammographic and sonographic evaluation. Radiol Clin north Am 1992; 30: 67-92.
• Wolfe jn. Breast patterns as an index of risk for developing breast cancer. Am J Roentgenol 1976; 126: 1130-1139.
• Boring C, Squire T, Tong T, et al. Cancer statistics CA . Cancer J Clin 1994; 44 7:
• -26.
• Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. The Lancet Vol 1998; 351; 1451-1465.
• Son HJ, Oh HR. Significance of follow -up mammography in estimating the effect of tamoxifen in breast cancer
• patients who have undergone surgery. AJR 1999; 173: 905-909.
• Ursin G, Pike CN, Spicer DV, Porrath 5/4 et al. Can mammographic densities predict effects of tamoxifen on the breast? J Hat! Cancer Inst 1996; 88: 128-129.
• Byrne C. Studying mammographic density implications for understanding breast cancer. J Natl Cancer Inst 1997; 89; 531-533.
• ,Oza AN, Boyd NF. Nammographic parenchymal paterns : a marker of breast cancer risk. Epidemiol Rev 1993; 15 : 196-208.
• Boyd NF, Byng JW, Jong RA, et al.
• Quantitative classification of
• mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995; 87:670-675.
• Byrne C, Schairer C, Wolfe JN, et al. Nammographic features and breast cancer risk: effects with time, age and menopause status. J Natl Cancer Inst 1995; 87: 1622-1629.
• Atkinson C, Warren R, Bingham 5/1, Day NE. Nammographic paterns as a predictive biomarker of breast cancer risk : effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 1999; 8: 863-866.
• Chow CR, Venzon D, Jones EC, Premkumar A, O'Shaughnessy J, Zujewski. Effect of tamoxifen on mammographic density. Cancer Epidemiol Biomarkers Prev 2000; 9: 917-921.